In fact, it has been demonstrated that subtle neuronal expression of human BACE1 resulted in AD phenotypes alongside systemic T2DM-like symptoms, suggesting that BACE1 inhibitors could be used for the treatment of T2DM-associated pathologies [32]. Here, BACE1 is linked to Alzheimer disease.